• linkedin
  • Increase Font
  • Sharebar

    A new year and new demands




    The Global Dermatology Drugs Market to 2023 report states there are more than 850 products in the dermatology pipeline worldwide with treatments for psoriasis leading the pack with approximately 282 treatments that are in development.

    This is followed by treatments for atopic dermatitis and acne with 136 and 70 products in development, respectively. But most of these, the report cautions, are in early development and only 3% are in pre-registration — most of which are biologics, generics and biosimilars.


    New in 2017 was brodalumab (Siliq/Valeant), an IL-17RA inhibitor approved by the FDA in February to treat moderate-to-severe plaque psoriasis.

    “By targeting IL-17RA, brodalumab has proven to be exceptionally efficacious with improvement of PASI 75 in over 80 percent, and approximately 70 percent of those patients achieved PASI 90 on brodalumab 210 mg by week 12 in three large phase three clinical trials,” wrote Stephen K. Tyring, M.D., Ph.D., of the University of Texas, in a review published in the Skin Therapy Letter.

    In July, the FDA approved guselkumab (Tremfya/Janssen), an IL-23 inhibitor for patients with moderate-to-severe plaque psoriasis. It joins a crowded field of biologics for plaque psoriasis that — in addition to secukinumab (Cosentyx/Novartis) approved in 2016; apremilast (Otezla/Celgene) approved in in 2014; ixekizumab (Taltz/Lilly) approved in 2016 — includes the IL-12 and 23 inhibitor ustekinumab (Stelara/Janssen); and, TNF inhibitors etanercept (Enbrel/Amgen), adalimumab (Humira/Abbvie), and infiximab (Remicade/ Janssen).



    Latest Tweets Follow